Slide 1: Second Quarter 2024 Results
SECOND QUARTER 2024 RESULTS August 2024
Slide 2: Disclaimer
Disclaimer Except for historical information contained herein, the matters set forth in this presentation are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward looking statements are not based on historical fact
Slide 3: Agenda
Agenda Operational Updates Financial Highlights Strategic Deliverables & YTD Progress Q&A
Slide 4: Q2'24 Operational Updates
Contributing to Better Health All @ Over the World Q2’24 Operational Updates
Slide 5: Robust Q2 Performance with Basic EPS Achieving NT$18.68 per share
Robust Q2 Performance with Bais EPS Achieving NT$18.68 per share Continued Expansion • H2’24 revenue totals $5.03bn, setting another historic high among the same period Global CDMO • Steady increase in top & bottom line. Revenue up 5% QoQ, develivering a quarterly historical high YoY* + 6 new client
Slide 6: Global CDMO – Growing Presence in the US Market
Global CDMO – Growing Presence in the US Market for both small and large molucules Plymouth + Maple Grove, Minnesota • Oral Solids • hard-gelatin capsules (IR/MR) • tablets, coated/ uncoated (IR/DR/ER) Oral Solid • Powders (oral and topical) • Tablets • Liquids (solutions) US Facility • Capsules + P
Slide 7: Global Commercial Sales – Diversifying Product Portfolio & Target Markets
Global Commercial Sales – Diversifying Product Portfolio & Target Markets to Boost Profitability Continued Portfolio • Integration of USL & TWi platforms: More than 80 commercial products, Expansion + Diversification including general generics, specialty generics , and PIV/ high-entry barrier generi
Slide 8: Q2'24 Financial Highlights
Contributing to Better Health All @ Over the World Q2’24 Financial Highlights
Slide 9: Strong Growth Momentum by "Dual-Engine" Strategies
Strong Growth Momentum by “Dual-Engine” Strategies Growth Drivers* Revenue Breakdown Global Commerical , Q2’24 = 72% CDMO, NT$5,027mn 28% Q2’23 = NT$3,139mn TW, 1% SW+BH, 7% DLS, 19% Branded NDA, 5% Other US Specialty, generics, 18% 50% *Including output for internal operations * BH + SW = Bora Heal
Slide 10: Q2'24 Financials
Q2’24 Financials Financial Highlights Key Financials YoY QoQ Exclu. One-time (in NTD millions, except for EPS) Q2'24 Q2'23 % Q1'24 % Q2'24 Revenue 5,027 3,139 60% 2,857 76% 5,027 COGS (3,076) (1,414) (1,352) (3,064) Gross Profits 1,951 1,724 13% 1,506 30% 1,964 GM % 39% 55% 53% 39% S&M (289) (94) 20
Slide 11: Another Record Year Expected with Outperforming Q2'24 Results
Another Record Year Expected with Outperforming Q2’24 Results Revenue (NT$’mn) Gross Profits (NT$’mn) 6,991 14,200 10,494 3,457 2,913 7,885 1,672 704 4,900 1,800 2020 2021 2022 2023 H1’24 Q2'24 GM (%) 39% 34% 28% 49% 44% 2020 2021 2022 2023 Q2'24 H1’24 Operating Income (NT$’mn) Net Profits (NT$’mn)
Slide 12: Strategic Investment into Tanvex – Deal Structure & Accounting Implications
Strategic Investment into Tanvex – Deal Structure & Accounting Implications Deal Structure Reference Post Deal Structure Date (tentative Q1’25) Accounting = Tanvex to issue implications： 保瑞藥業 72,707,800 保瑞藥業 1. Tanvex will be shares to Bora “Long term equity in exchange of Bora Bio’s 30.5% investmen
Slide 13: Strategic Deliverables & YTD Progress
Strategic Deliverables & YTD Progress
Slide 14: 3 Major Deals to Form a Global CDMO Platform YTD'2024
3 Major Deals to Form a Global CDMO Platform YTD’2024 Large molecule production capacit Sterile Injectable, Fill/Finish Strategic Alliance Camden, Baltimore ✓ Form the strategic alliance through subsidiary 1st US facility with merger and acquisition ✓ Acquire US based and FDA approved site for large
Slide 15: Smooth USL Integration with Strong Growth Momentum
Smooth USL Integration with Strong Growth Momentum ✓ USL contribute NTD 2 billion revenue for 2024Q2 (attribute to Global Commercial Sale) ✓ Streamline Integration Step by Step • OPEX efficiency improvement 1 TWi/USL portfolio • 3PL transfer integration is completed • TWi/USL portfolio integration b
Slide 16: Camden Facility to officially contribute in Q3'24
Camden Facility to officially contribute in Q3’24 Camden, Baltimore 127,900* ft2 4 Lines ~300 Employees ✓ 4 filling line for finished product Including 2 filling line sterile bottle (2 RABS vial) and 1 bottle/injectable production line. The production is capable to produce 60,000 bottle per batch.
Slide 17: Strategic Alliance with Tanvex to Complete Biologics Capabilities in the US
Strategic Alliance with Tanvex to Complete Biologics Capabilities in the US Drug Substance Commercialization Drug Product and Capacity Complex Biologics Platform Sterile Fill/Finish Technology Technology & Capacity Extend the order cycle for Extend the order cycle for current customer current c
Slide 18: Truly Complete CDMO Capabilities to Grasp Market Opportunities
Truly Complete CDMO Capabilities to Grasp Market Opportunities CDMO 服務類型 藥品開發 藥品製造 藥品包裝 (Type of Drug Product Development Drug Product Manufacturing Drug Packaging Service) 服務內容 採購 (Sourcing) 配方製造 (Formulation) 初級、二級、三級包裝 (Service 試件製造 (Specimen Manufacture) (Primary, Secondary, Tertiary Packaging)
Slide 19: Business continues to grow + M&A/strategic alliances, Maximize shareholder value
Business continues to grow + M&A/strategic alliances, Maximize shareholder value Organic Growth Unit: NT$ mn M&A Sales + USL & Organic Growth 14,200 Net Income Camden M&A 10,494 Facility Organic Growth + tanvex 4,900 Strategic 3,072 Alliances 1,372 1,529 1,800 218 238 283 358 1,402 4 97 17 34 25 15
Slide 20: Largest CDMO and Pharma manufacturer in Taiwan with aggressive global growth plan
LARGEST CDMO and Pharma manufacturer in Taiwan with aggressive global growth plan Experienced LEADERSHIP team STRONG GROWTH in with proven track record of delivering CDMO and Rx Market continues to results and consistently outperforming have high demand and attractive the market CAGR 保瑞集團 Bora Group